Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alteplase in Acute Central Retinal Artery Occlusion
NCT03197194Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Jun 2018
- Primary completion
- Jan 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tissue-plasminogen activator in central retinal artery occlusion (CRAO) (2 arms), sponsored by CHU de Nantes. Primary endpoint: Visual acuity improvement after treatment at 1 month. Started Jun 2018; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on NCT03197194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197194.